Page 1

1/29/26 , 5:32 PM Document EX - 99.1 2 a20210331ex991 earningsrele.htm EX - 99.1 endo Exhibit 99.1 ENDO REPORTS FIRST - QUARTER 2021 FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE DUBLIN , May 6 , 2021 -- Endo International plc ( NASDAQ : ENDP ) today reported financial results for the first - quarter ended March 31 , 2021 . " I am proud of the continued strong execution across each of Endo's business segments as reflected by our better than expected first- quarter 2021 results . During the quarter , our Branded Pharmaceuticals segment returned to growth , driven by strong demand for XIAFLEX® and other physician administered products , " said Blaise Coleman , President and Chief Executive Officer at Endo . " In addition , we continued executing against our ongoing business transformation initiatives and achieved an important strategic milestone with the launch of QWO® , the first and only FDA - approved injectable treatment for cellulite . We are very encouraged by QWO®'s initial market reception and are excited by our significant opportunity to bring this innovative treatment to market . " FIRST - QUARTER FINANCIAL PERFORMANCE ( in thousands , except per share amounts ) Three Months Ended March 31 , 2021 2020 Change Total Revenues , Net $ 717,919 $ 820,405 ( 12 ) % Reported Income from Continuing Operations $ 47,059 $ 157,581 ( 70 ) % Reported Diluted Weighted Average Shares 238,671 233,014 2 % Reported Diluted Net Income per Share from Continuing Operations $ 0.20 $ 0.68 ( 71 ) % Reported Net Income $ 41,524 $ 129,930 ( 68 ) % Adjusted Income from Continuing Operations ( 2 ) $ 174,917 $ 220,400 ( 21 ) % Adjusted Diluted Weighted Average Shares ( 1 ) ( 2 ) 238,671 233,014 2 % Adjusted Diluted Net Income per Share from Continuing Operations ( 2 ) Adjusted EBITDA ( 2 ) $ 0.73 $ 0.95 ( 23 ) % $ 364,715 $ 421,126 ( 13 ) % ( 1 ) Reported Diluted Net Income per Share from Continuing Operations is computed based on weighted average shares outstanding and , if there is income from continuing operations during the period , the dilutive impact of ordinary share equivalents outstanding during the period . In the case of Adjusted Diluted Weighted Average Shares , Adjusted Income from Continuing Operations is used in determining whether to include such dilutive impact . ( 2 ) The information presented in the table above includes non - GAAP financial measures such as " Adjusted Income from Continuing Operations , " " Adjusted Diluted Weighted Average Shares , " " Adjusted Diluted Net Income per Share from Continuing Operations " and " Adjusted EBITDA . " Refer to the " Supplemental Financial Information " section below for reconciliations of certain non - GAAP financial measures to the most directly comparable GAAP financial measures . CONSOLIDATED RESULTS Total revenues were $ 718 million in first - quarter 2021 , a decrease of 12 % compared to $ 820 million during the same period in 2020 . This result was primarily attributable to decreased Generic Pharmaceuticals and Sterile Injectables segment revenues . 1 https://www.sec.gov/Archives/edgar/data/1593034/000159303421000059/a20210331ex991 earningsrele.htm 1/16